Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma
This designation potentially allows Aduro seven years of limited marketing exclusivity in the United States if it is the first to obtain FDA marketing approval for mesothelioma, and qualifies the company for grant funding to offset the cost of clinical…